Today we’re announcing an oversubscribed funding round of 2.8 M EUR that will accelerate our journey to transform how biomedicines are developed and produced through real-time data.
Our CEO, Erik Martinsson, comments on the round:
As ArgusEye embarks on its scale-up phase, our focus is twofold: expanding our market footprint geographically and diversifying our product offerings to encompass the entire pharmaceutical process chain, from upstream cell growth to downstream purification and late-stage formulation as well as GMP production. This strategic approach aligns with our commitment to deliver cutting-edge solutions that address the evolving needs of the biopharmaceutical industry and our vision to enable a more sustainable and democratic reach of biomedicines, transforming biopharma manufacturing through real-time inline quality control.